IL312138A - Pharmaceutical formulation comprising anti-ox40 monoclonal antibody - Google Patents

Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Info

Publication number
IL312138A
IL312138A IL312138A IL31213824A IL312138A IL 312138 A IL312138 A IL 312138A IL 312138 A IL312138 A IL 312138A IL 31213824 A IL31213824 A IL 31213824A IL 312138 A IL312138 A IL 312138A
Authority
IL
Israel
Prior art keywords
monoclonal antibody
pharmaceutical formulation
formulation containing
pharmaceutical
monoclonal
Prior art date
Application number
IL312138A
Other languages
English (en)
Hebrew (he)
Original Assignee
Inmagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmagene Pte Ltd filed Critical Inmagene Pte Ltd
Publication of IL312138A publication Critical patent/IL312138A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL312138A 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody IL312138A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021124200 2021-10-15
CN2022118065 2022-09-09
PCT/CN2022/125017 WO2023061424A1 (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Publications (1)

Publication Number Publication Date
IL312138A true IL312138A (en) 2024-06-01

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312138A IL312138A (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Country Status (13)

Country Link
US (1) US20250282882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538140A (cg-RX-API-DMAC7.html)
KR (1) KR20240109250A (cg-RX-API-DMAC7.html)
CN (1) CN118541166A (cg-RX-API-DMAC7.html)
AU (1) AU2022367611A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235879A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001157A1 (cg-RX-API-DMAC7.html)
IL (1) IL312138A (cg-RX-API-DMAC7.html)
MX (1) MX2024004619A (cg-RX-API-DMAC7.html)
PE (1) PE20241351A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323280A (cg-RX-API-DMAC7.html)
WO (1) WO2023061424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136116A4 (en) * 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN117257936B (zh) * 2023-10-30 2026-05-01 杭州博之锐生物制药有限公司 一种阿达木单抗组合物
WO2025185555A1 (en) * 2024-03-04 2025-09-12 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof
WO2026130530A1 (en) * 2024-12-19 2026-06-25 Akeso Biopharma Co., Ltd. Antibody formulations with reduced aggregation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
ES3014697T3 (en) * 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
TWI726426B (zh) * 2018-09-25 2021-05-01 大陸商信達生物製藥(蘇州)有限公司 包含抗ox40抗體的製劑、其製備方法及其用途
EP3999537A1 (en) * 2019-07-19 2022-05-25 Ichnos Sciences SA Lyophilized antibody formulation
TW202144005A (zh) * 2020-03-25 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ox40抗體醫藥組成物及其用途

Also Published As

Publication number Publication date
CN118541166A (zh) 2024-08-23
WO2023061424A1 (en) 2023-04-20
CL2024001157A1 (es) 2024-11-15
KR20240109250A (ko) 2024-07-10
TW202323280A (zh) 2023-06-16
EP4415754A4 (en) 2025-09-24
US20250282882A1 (en) 2025-09-11
JP2024538140A (ja) 2024-10-18
CA3235879A1 (en) 2023-04-20
PE20241351A1 (es) 2024-07-03
AU2022367611A1 (en) 2024-05-02
MX2024004619A (es) 2024-07-12
EP4415754A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
EP4415754A4 (en) PHARMACEUTICAL FORMULATION COMPRISING AN ANTI-OX40 MONOCLONAL ANTIBODY
KR102587633B9 (ko) 수의학적 용도를 위한 인터류킨-31 단클론성 항체
EP3705134A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
EP4361273A4 (en) ANTI-CTLA-4 ANTIBODIES
EP3459973A4 (en) Anti-human pd-l1 humanized monoclonal antibody and application thereof
EP3441086A4 (en) MONOCLONAL ANTI-PD-1 ANTIBODY
KR102660249B9 (ko) 항-her2 항체 약물 접합체 약학 제제
SG11202103670XA (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
EP4023673A4 (en) ANTI-BCMA HUMANIZED MONOCLONAL ANTIBODY WITH HUMAN-MONKEY CROSS-REACTIVITY
EP4074338A4 (en) PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY
IL285134A (en) Therapeutic antibody formulation
DK3347054T3 (da) Dosisregimer til anti-TF-antistoflægemiddelkonjugater
IL316653A (en) Antibody drug conjugates
EP3746120A4 (en) ANTI-PD-1 ANTIBODY
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTI-HER3 ANTIBODY
IL304800A (en) Bispecific antibody
EP4327823A4 (en) BISPECIFIC ANTI-CLDN4/ANTI-CD137 ANTIBODY
IL287531A (en) Monoclonal antibody that binds specifically to gitr
EP3851121A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING HUMAN MONOCLONAL ANTI-IL-33 ANTIBODIES
IL287443A (en) Dosage regimens for and compositions including anti-rsv antibodies
EP4144370A4 (en) BISPECIFIC ANTIBODY
IL282742A (en) Monoclonal antibody that specifically binds to cd20
DK4157876T3 (da) Anti-pd-1-antistoffer
EP3888678A4 (en) Anti-pd-l1 antibody preparation
EP4426744A4 (en) PHARMACEUTICAL COMPOSITIONS OF HUMANIZED ANTI-CD40 ANTIBODIES